Literature DB >> 8040331

Antimyenteric neuronal antibodies in scleroderma.

S Howe1, E Y Eaker, J E Sallustio, C Peebles, E M Tan, R C Williams.   

Abstract

The pathogenesis of gastrointestinal (GI) dysmotility in scleroderma is incompletely understood, although previous studies have proposed a neuropathic mechanism. We studied patients with scleroderma as compared with other connective tissue disease patients and normal controls for the presence of circulating antibodies to myenteric neurons. Serial dilutions of sera were overlaid on rat intestine, double-labeled with antineurofilament antibody as a myenteric plexus marker, and imaged using indirect immunofluorescence techniques. High titer sera (> or = 1:50) from 19 out of 41 scleroderma patients stained myenteric neurons, whereas none of 22 normals or 5 patients with idiopathic GI dysmotility were positive. Although 6 out of 20 SLE and 6 out of 10 mixed connective tissue disease patients' sera stained myenteric plexus neurons, when positive sera were absorbed with calf thymus extract to remove antinuclear antibody, 15 scleroderma sera, 0 SLE, and 2 mixed connective tissue disease patients retained positive staining of myenteric neurons. Western blotting using actin and neuronal intermediate filament preparations failed to show immunoreactivity with scleroderma sera containing antimyenteric neuronal antibodies. Paraneoplastic sera associated with GI dysmotility stained myenteric neurons in a different pattern than seen with scleroderma sera. A positive correlation between the presence of Raynaud's phenomenon and antimyenteric neuronal antibodies was observed in scleroderma patients. Our results indicate that IgG antibodies reacting with myenteric neurons are present in many patients with scleroderma. Although the neuronal antigen has not yet been identified, the presence of myenteric neuronal antibodies in patients with GI dysmotility and scleroderma suggests a neuropathic process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040331      PMCID: PMC296156          DOI: 10.1172/JCI117395

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  APERISTALSIS OF THE ESOPHAGUS IN PATIENTS WITH CONNECTIVE-TISSUE DISORDERS AND RAYNAUD'S PHENOMENON.

Authors:  M B STEVENS; P HOOKMAN; C I SIEGEL; J R ESTERLY; L E SHULMAN; T R HENDRIX
Journal:  N Engl J Med       Date:  1964-06-04       Impact factor: 91.245

2.  Progressive systemic sclerosis sine scleroderma.

Authors:  G P RODNAN; R H FENNELL
Journal:  JAMA       Date:  1962-05-26       Impact factor: 56.272

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin.

Authors:  J A Spudich; S Watt
Journal:  J Biol Chem       Date:  1971-08-10       Impact factor: 5.157

5.  Duodenal myoelectric activity in scleroderma. Abnormal responses to mechanical and hormonal stimuli.

Authors:  A J DiMarino; G Carlson; A Myers; H R Schumacher; S Cohen
Journal:  N Engl J Med       Date:  1973-12-06       Impact factor: 91.245

6.  The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease.

Authors:  S Cohen; R Fisher; W Lipshutz; R Turner; A Myers; R Schumacher
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

7.  Isolation of filaments from brain.

Authors:  M L Shelanski; S Albert; G H DeVries; W T Norton
Journal:  Science       Date:  1971-12-17       Impact factor: 47.728

8.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.

Authors:  R M Bernstein; J C Steigerwald; E M Tan
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

9.  Gastrointestinal regulatory peptides in systemic sclerosis.

Authors:  A Akesson; R Ekman
Journal:  Arthritis Rheum       Date:  1993-05

10.  Progressive systemic sclerosis of the gastrointestinal tract and hereditary hollow visceral myopathy: two distinguishable disorders of intestinal smooth muscle.

Authors:  M D Schuffler; R G Beegle
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

View more
  23 in total

Review 1.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

Review 2.  Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management.

Authors:  Genevieve Gyger; Murray Baron
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 3.  [Scleroderma associated autoantibodies - clinical and diagnostic relevance].

Authors:  R Mierau; E Genth
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 4.  Intestinal Involvement in Systemic Sclerosis: A Clinical Review.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Dimitrios Daoussis; Stamatis-Nick Liossis; Spyros Potamianos
Journal:  Dig Dis Sci       Date:  2018-02-21       Impact factor: 3.199

5.  Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study.

Authors:  G N Verne; J E Sallustio; E Y Eaker
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

6.  Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.

Authors:  Yossra Suliman; Suzanne Kafaja; Sunny J Oh; Mohamed Alemam; Gianluca Bagnato; Giuseppina Abignano; Ram Raj Singh; Gillian Barlow; Xiaochen Liu; Isela Valera; Walter Morales; Ali Rezaie; Mark Pimentel; Francesco Del Galdo; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2020-11-24       Impact factor: 2.980

Review 7.  Measuring response in the gastrointestinal tract in systemic sclerosis.

Authors:  Dinesh Khanna; Vivek Nagaraja; Heather Gladue; William Chey; Mark Pimentel; Tracy Frech
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

8.  Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.

Authors:  Jagmohan Singh; Vaibhav Mehendiratta; Francesco Del Galdo; Sergio A Jimenez; Sidney Cohen; Anthony J DiMarino; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

Review 9.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

10.  A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).

Authors:  C G P Roberts; L K Hummers; W J Ravich; F M Wigley; G M Hutchins
Journal:  Gut       Date:  2006-03-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.